Health Plan Best Practices for the Evolving Management of Atopic Dermatitis

• Release Date: March 15, 2023
• Expiration Date: August 31, 2024
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

Expert Faculty Presenters:

Steven S. Kheloussi PharmD, MBA Assistant Professor of Pharmacy Practice Wilkes University Click here for biography Dana McCormick, RPh, FAMCP Director of Pharmacy Blue Cross Blue Shield of Texas Click here for biography Jennifer Schoch, MD, FAAD Associate Professor Pediatric Dermatology Department of Dermatology University of Florida Click here for biography Michele Guadalupe, MPH Director of Advocacy and Access National Eczema Association Click here for biography

Target Audience
The target audience consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
An action plan to enhance knowledge of clinical, economic, and humanistic burden of AD is needed by managed care and payer decision makers to enact health care benefit policy strategies to reduce the disease burden and enhance the potential for optimal treatment outcomes. These health care professionals also need increased knowledge of recently approved and emerging AD therapies in order to develop and implement AD benefit design strategies that support an improvement in overall patient quality of life and clinical outcomes. This includes knowledge of the heterogeneity of the presentation of AD and the need to align specific therapies with specific patient types. Furthermore, it is clear that payers can benefit from dermatology providers’ experience and expertise when creating PA criteria in order to streamline utilization controls in order to improve patient access to appropriate therapy.

Educational Objectives
After completing this activity, the participant should be better able to:

• Evaluate the challenges of treating patients with AD and its accompanying comorbidities
• Employ timely referral and collaborative, multidisciplinary management of patients with AD
• Utilize treatment optimization approaches to balance costs with improved outcomes in AD disease management
• Discuss payer benefit management strategies to minimize common barriers to AD therapies and improve access to appropriate care

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER), the National Eczema Association (NEA), and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Medical Education Resources designates this enduring activity for a maximum of 1.0 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hours.

Pharmacy Education
Medical Education Resources (MER) designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0003680-9999-23-143-H01-P
This activity is certified as Knowledge-based CPE.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF CONFLICTS OF INTEREST
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, the National Eczema Association (NEA), and Impact Education, LLC, and/or, Sanofi and Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.
For Pharmacists: Upon successfully completing the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.